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Special issue on Molecular Basis of Multiple SclerosisWith more than 44,200 publications relating to Multiple Sclerosis
(MS) during the last 10 years (Pubmed and ISI Thompson, as of
October 19th 2010), it has become extremely challenging for
students, post-doctoral fellows, academic investigators and clinicians
to follow this tremendously active ﬁeld of research. Furthermore, the
annual number of manuscripts listing MS as a keyword or including
MS in the abstract has doubled from 2594 in 2000, to 5996 in 2009
(see Table 1). At this pace, it is more difﬁcult to identify, retrieve and
analyze important contributions, even in very narrow and sub-
specialized ﬁelds of MS science.
The current special issue of BBA is certainly not a thorough review
on the topic of molecular and cellular events involved in the
pathophysiology of MS. Instead, reviews included in this issue try to
convey the thinking and most signiﬁcant contributions from some of
the leading MS and experimental autoimmune encephalitis (EAE)
experts in their respective sub-specialized ﬁelds. My question to them
was simple: “what happened in your ﬁeld during the last 10 years and
how could you convey this information to a broad readership”?Table 1
Number of Scientiﬁc Publication on the Topic of Multiple Sclerosis between 1980
and 2009. Number of publications on Amyotrophic Lateral Sclerosis is shown as a
comparative. (Source: Pubmed (ncbi.nlm.nih.gov/pubmed) and ISI Thompson
(isiknowledge.com/)).
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doi:10.1016/j.bbadis.2010.12.003Despite more than one hundred years of research in MS and EAE,
there is a very important number of scientiﬁc issues and controversies
yet to be resolved. For example, as we now know more about the
involvement of neuronal and axonal damage in the pathology of MS,
the exact nature of this damage and the mediators involved are yet to
be identiﬁed. Furthermore, whether axonal damage occurs before or
as a consequence of demyelination is still uncertain. The inﬂuence of
new cytokines on CNS autoimmune inﬂammation was also identiﬁed
during that period (IL-23, IL-21 and IL-35, to name only those) and
new roles for “old” cytokines were identiﬁed (TGFβ and IL-6 and their
role on IL-17 expression by T lymphocytes). This was the basis for a
major turmoil in the ﬁeld with variable degrees of paradigm change,
or at least questioning. MS and EAE immunologists also remain
undecided about the exact role and respective contributions of
various subsets of myeloid antigen presenting cells, including
microglia, dendritic cells and macrophages in autoimmune CNS
demyelination. Whether one or all of these cells are essential to the
disease process and whether they contribute differentially to CNS
damage and repair is still actively debated.
The presence of these controversies and scientiﬁc issues highlights
the fact that despite active and intense research on MS (and EAE), we
remain largely unaware, even sometimes ignorant of the exact
cellular and molecular events, or cascade of events that regulate this
complex and unpredictable disease.
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